{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:25:17Z","timestamp":1790706317358,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":1540,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1111\/ajt.14939","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T05:59:24Z","timestamp":1526450364000},"page":"2305-2313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts"],"prefix":"10.1016","volume":"18","author":[{"given":"Matthew J.","family":"Everly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustimbo","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Gebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1111\/ajt.14939_bib1","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1600-6143.2011.03563.x","article-title":"Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy","volume":"11","author":"Loupy","year":"2011","journal-title":"Am J Transplant."},{"issue":"13","key":"10.1111\/ajt.14939_bib2","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1111\/ajt.14939_bib3","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.14939_bib4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e31827d62e3","article-title":"Incidence and impact of de novo donor-specific alloantibody in primary renal allografts","volume":"95","author":"Everly","year":"2013","journal-title":"Transplantation."},{"issue":"11","key":"10.1111\/ajt.14939_bib5","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/j.1600-6143.2009.02799.x","article-title":"Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure","volume":"9","author":"Einecke","year":"2009","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.14939_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/TP.0b013e31817c4cb8","article-title":"Human leukocyte antigen antibodies and chronic rejection: from association to causation","volume":"86","author":"Terasaki","year":"2008","journal-title":"Transplantation."},{"issue":"9","key":"10.1111\/ajt.14939_bib7","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2007.01895.x","article-title":"Transplant glomerulopathy: subclinical incidence and association with alloantibody","volume":"7","author":"Gloor","year":"2007","journal-title":"Am J Transplant."},{"issue":"6","key":"10.1111\/ajt.14939_bib8","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/ajt.14161","article-title":"The value of protocol biopsies to identify patients with de novo donor-specific antibody at high risk for allograft loss","volume":"17","author":"Schinstock","year":"2017","journal-title":"Am J Transplant."},{"issue":"8","key":"10.1111\/ajt.14939_bib9","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/00007890-200210270-00025","article-title":"All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies","volume":"74","author":"Lee","year":"2002","journal-title":"Transplantation."},{"issue":"6","key":"10.1111\/ajt.14939_bib10","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/ajt.12212","article-title":"De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients","volume":"13","author":"Kaneku","year":"2013","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.14939_bib11","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","article-title":"Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients","volume":"11","author":"Stegall","year":"2011","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.14939_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1111\/ajt.14939_bib13","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/ki.2012.190","article-title":"Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation","volume":"82","author":"DeVos","year":"2012","journal-title":"Kidney Int."},{"key":"10.1111\/ajt.14939_bib14","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1097\/TP.0000000000000216","article-title":"De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation","volume":"98","author":"Heilman","year":"2014","journal-title":"Transplantation."},{"issue":"10","key":"10.1111\/ajt.14939_bib15","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/TP.0b013e3182139da1","article-title":"Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes","volume":"91","author":"Cooper","year":"2011","journal-title":"Transplantation."},{"issue":"1","key":"10.1111\/ajt.14939_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-6143.2012.04291.x","article-title":"Five-year outcomes in living donor kidney transplants with a positive crossmatch","volume":"13","author":"Bentall","year":"2013","journal-title":"Am J Transplant."},{"issue":"5","key":"10.1111\/ajt.14939_bib17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.TP.0000441362.11232.48","article-title":"Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients","volume":"97","author":"Everly","year":"2014","journal-title":"Transplantation."},{"issue":"2\u20133","key":"10.1111\/ajt.14939_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1385\/IR:22:2-3:199","article-title":"Studies of the humoral immune response","volume":"22","author":"Kelsoe","year":"2000","journal-title":"Immunol Res."},{"issue":"3","key":"10.1111\/ajt.14939_bib19","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0952-7915(00)00216-8","article-title":"B lymphocyte activation by contact-mediated interactions with T lymphocytes","volume":"13","author":"Bishop","year":"2001","journal-title":"Curr Opin Immunol."},{"issue":"12","key":"10.1111\/ajt.14939_bib20","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.4049\/jimmunol.0803783","article-title":"B7-1\/2 (CD80\/CD86) direct signaling to B cells enhances IgG secretion","volume":"183","author":"Rau","year":"2009","journal-title":"J Immunol."},{"issue":"4","key":"10.1111\/ajt.14939_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1111\/ajt.14939_bib22","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/ajt.13830","article-title":"Long-term outcomes in Belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study","volume":"16","author":"Durrbach","year":"2016","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.14939_bib23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.14939_bib24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.14939_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant."},{"issue":"16","key":"10.1111\/ajt.14939_bib26","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1161\/CIRCULATIONAHA.104.485003","article-title":"Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease","volume":"112","author":"Lietz","year":"2005","journal-title":"Circulation."},{"issue":"5","key":"10.1111\/ajt.14939_bib27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/TP.0b013e3181837626","article-title":"Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels","volume":"86","author":"Issa","year":"2008","journal-title":"Transplantation."},{"issue":"5","key":"10.1111\/ajt.14939_bib28","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation","volume":"12","author":"Liefeldt","year":"2012","journal-title":"Am J Transplant."},{"issue":"11","key":"10.1111\/ajt.14939_bib29","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1111\/ajt.14353","article-title":"Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function","volume":"17","author":"Adams","year":"2017","journal-title":"Am J Transplant."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.14939","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522097027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522097027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajt.14939\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:21:27Z","timestamp":1761628887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522097027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1600613522097027"],"URL":"https:\/\/doi.org\/10.1111\/ajt.14939","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.14939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}